Business Context and Reporting Period
This Form 8-K reports on the 2018 Annual Meeting of Stockholders held by TherapeuticsMD, Inc. on June 25, 2018. The filing details the voting results for three specific proposals submitted to shareholders.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a current report regarding corporate governance events and does not contain financial performance data.
Material Changes and Voting Results
Stockholders voted on and approved the following three proposals:
- Proposal 1 (Election of Directors): All eleven nominees were elected with zero votes against. The total votes cast ranged from approximately 129.5 million to 130.9 million "For" each nominee.
- Proposal 2 (Say-on-Pay): The non-binding advisory vote on executive compensation for fiscal 2017 was approved. Approximately 126.6 million votes were cast "For" versus 4.4 million "Against."
- Proposal 3 (Auditor Ratification): The appointment of Grant Thornton, LLP as the independent auditor for the fiscal year ending December 31, 2018, was ratified. Approximately 185.0 million votes were cast "For" versus 2.0 million "Against."
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, contingencies, or unusual items. The document is limited to the reporting of the annual meeting outcomes.
Investor Verification Checklist
- Verify the full list of elected directors and their tenure terms in the 2018 Proxy Statement.
- Review the 2018 Proxy Statement for details on the executive compensation package approved in Proposal 2.
- Confirm the scope of services and fees for Grant Thornton, LLP as the newly ratified auditor.
- Check subsequent filings (10-K or 10-Q) for the actual financial performance metrics not included in this 8-K.